UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 565

Sortiert nach

PCSK9 and Atherosclerosis - Lipids and Beyond

Journal of Atherosclerosis and Thrombosis, 2017/05/01, Vol.24(5), pp.462-472

2017

Volltextzugriff (PDF)

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering

Cardiovascular research, 2016-10, Vol.112 (1), p.429-442

2016

Volltextzugriff (PDF)

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Journal of the American College of Cardiology, 2018-01, Vol.71 (2), p.177-192

2018

Volltextzugriff (PDF)

The Severe Hypercholesterolemia Phenotype

Journal of the American College of Cardiology, 2014-05, Vol.63 (19), p.1935-1947

2014

Volltextzugriff (PDF)

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE

Endocrine practice, 2017-04, Vol.23 (Suppl 2), p.1-87

2017

Volltextzugriff (PDF)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

Journal of managed care & specialty pharmacy, 2016-06, Vol.22 (6), p.641

2016

Volltextzugriff (PDF)

Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis

Journal of the American College of Cardiology, 2012-12, Vol.60 (23), p.2372-2379

2012

Volltextzugriff (PDF)

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms

Circulation (New York, N.Y.), 2014-07, Vol.130 (5), p.431-441

2014

Volltextzugriff (PDF)

Local effects of human PCSK9 on the atherosclerotic lesion

The Journal of pathology, 2016-01, Vol.238 (1), p.52-62

2016

Volltextzugriff (PDF)

Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection

Journal of lipid research, 2024-06, Vol.65 (6), p.100568, Article 100568

2024

Volltextzugriff (PDF)

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

Circulation research, 2013-12, Vol.113 (12), p.1290-1295

2013

Volltextzugriff (PDF)

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis[S]

Journal of lipid research, 2015-08, Vol.56 (8), p.1449-1460

2015

Volltextzugriff (PDF)

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

Cardiovascular research, 2016-05, Vol.110 (2), p.268-278

2016

Volltextzugriff (PDF)

HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events

Clinical chemistry (Baltimore, Md.), 2011-03, Vol.57 (3), p.392-410

2011

Volltextzugriff (PDF)

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein

Archives of medical research, 2015-07, Vol.46 (5), p.379-391

2015

Volltextzugriff (PDF)

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size

Journal of clinical lipidology, 2018-09, Vol.12 (5), p.1313-1323

2018

Volltextzugriff (PDF)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease

F1000 research, 2017, Vol.6, p.134-134

2017

Volltextzugriff (PDF)

Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis

Nature medicine, 2009-12, Vol.15 (12), p.1383-1391

2009

Volltextzugriff (PDF)

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

Journal of clinical medicine, 2024-02, Vol.13 (4), p.943

2024

Volltextzugriff (PDF)

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Journal of the American Heart Association, 2019-02, Vol.8 (4), p.e010932-e010932

2019

Volltextzugriff (PDF)

PCSK9

Circulation research, 2018-05, Vol.122 (10), p.1420-1438

2018

Volltextzugriff (PDF)

Role of PAI-1 in hepatic steatosis and dyslipidemia

Scientific reports, 2021-01, Vol.11 (1), p.430-430, Article 430

2021

Volltextzugriff (PDF)

Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease

The Journal of biological chemistry, 2010-11, Vol.285 (47), p.36958-36968

2010

Volltextzugriff (PDF)

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

The Journal of clinical investigation, 2022-06, Vol.132 (12), p.1-13

2022

Volltextzugriff (PDF)

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Nature, 2007-06, Vol.447 (7147), p.959-965

2007

Volltextzugriff (PDF)

1 – 25 von 565

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(535)
Mit Volltextzugriff
(493)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(370)
Life Sciences & Biomedicine
(347)
Humans
(229)
Animals
(161)
Cardiovascular System & Cardiology
(149)
Female
(138)
Male
(134)
Mice
(118)
Cardiac & Cardiovascular Systems
(108)
Biological And Medical Sciences
(91)
Atherosclerosis
(87)
Medical Sciences
(85)
Middle Aged
(85)
Peripheral Vascular Disease
(80)
Mice, Inbred C57bl
(74)
Cholesterol
(66)
Mice, Knockout
(58)
Adult
(57)
Aged
(57)
Biochemistry & Molecular Biology
(46)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

PCSK9 and Atherosclerosis - Lipids and Beyond

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

The Severe Hypercholesterolemia Phenotype

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms

Local effects of human PCSK9 on the atherosclerotic lesion

Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection

Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis[S]

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease

Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

PCSK9

Role of PAI-1 in hepatic steatosis and dyslipidemia

Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

Suchergebnisse filtern